

Figure S.1: Expression of *EGFR* splice variants, *GAPDH* and *MMP2* 48 hours after the application of three siRNA constructs (*siRNA_{nonsense}* as control, *siRNA_{ALL}*, *siRNA_I*) the mRNA levels of all *EGFR* splice variants, full-length *EGFR* (*EGFR* splice variant I), *EGFR* splice variant IV, *GAPDH*, and *MMP2* were measured and normalized to *HPRT*. The analysis was performed with at least three independent experiments in the cell line SF767. Compared to the control experiments the *siRNA_{ALL}* and the *siRNA_I* reduced the levels of mRNA of all *EGFR* splice variants by about 70% and of *EGFR* splice variant I by about 75%. The *EGFR* splice variant IV was reduced only by the siRNA *siRNA_{ALL}* and *siRNA_I* did not affect the mRNA level. As expected, compared to the control experiment the mRNA levels of *GAPDH* and *MMP2* are not reduced.




Figure S.2: **log₂-fold changes of the qPCR expression levels for cell lines SF767 and LNZ308**
 The cell lines (SF767 and LNZ308) were stimulated with the ligand EGF (50ng/ml for 24 hours) and the gene expressions of *CKAP2L*, *ROCK1*, *TPR*, *ALDH4A1* and *GALNS* were measured by qPCR experiments. The analysis were performed with at least three independent experiments for each cell lines. The log₂-fold changes of the qPCR experiments were calculated for control without EGF vs control with EGF stimulation based on the $\Delta\Delta CT$ -values compared to GAPDH. By the comparison of log₂-fold changes of the cell lines SF767 and LNZ308, we could validate four genes (*CKAP2L*, *ROCK1*, *TPR*, and *GALNS*) by having overlapping error bars and detect that *ALDH4A1* was differently down-regulated in both cell lines.